<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834559</url>
  </required_header>
  <id_info>
    <org_study_id>uni-koeln-1782</org_study_id>
    <secondary_id>2015-004731-12</secondary_id>
    <nct_id>NCT02834559</nct_id>
  </id_info>
  <brief_title>Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.</brief_title>
  <acronym>PRIVENT</acronym>
  <official_title>Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Clinical Trials Centre Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacy of the University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Medical Statistics, Informatics and Epidemiology (IMSIE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Köln</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effectiveness of a simple treatment to prevent proliferative
      vitreoretinopathy (PVR).

      Intraoperative intravitreal 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) is
      used as a prophylactic therapy in high-risk patients with primary rhegmatogenous retinal
      detachment (RRD). Our major motivation is to reduce the incidence of PVR in the group that
      receives the trial drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proliferative vitreoretinopathy (PVR) is a common cause for postoperative failure after
      vitreoretinal surgery for primary RRD. There is no standard-therapy to prevent PVR. Several
      attempts using chemotherapeutic agents have been undertaken to prevent this
      proliferation-process, but none of these was introduced into routine clinical practice.

      Until recently, it has been challenging to identify patients with high risk for postoperative
      PVR formation. This is especially important, because in this trial treatment with the trial
      drug will be restricted to patients at high risk for PVR only.

      Patients are assigned to the following treatment arms (1:1):

      (A) Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight
      heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in
      high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous
      retinal detachment (RRD).

      Versus:

      (B) Routinely used intraocular infusion with balanced salt solution (BSS) during routine PPV.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proliferative Vitreoretinopathy (PVR) grade CP (posterior - full thickness retinal folds in clock hours) 1 or higher [yes/no]</measure>
    <time_frame>within 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PVR grade CP 1 or higher [yes/no]</measure>
    <time_frame>within 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PVR grade CA (anterior - full thickness retinal folds in clock hours) 1 or higher [yes/no]</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of PVR (PVR grade CA 1-12, PVR grade CP 1-12 (in clock hours))</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA) measured by ETDRS charts</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal reattachment after primary intervention [yes/no]</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of retinal re-detachments and if present due to PVR [yes/no]</measure>
    <time_frame>within 6 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and extent of surgical procedures necessary to achieve retinal reattachment</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of at least one drug-related adverse event that affects the study eye [yes/no]</measure>
    <time_frame>within 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">560</enrollment>
  <condition>Rhegmatogenous Retinal Detachment</condition>
  <condition>High-risk for Proliferative Vitreoretinopathy (PVR)</condition>
  <arm_group>
    <arm_group_label>Adjuvant therapy with 5-FU and LMWH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil and low molecular weight heparin</intervention_name>
    <description>Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).</description>
    <arm_group_label>Adjuvant therapy with 5-FU and LMWH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).</description>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary rhegmatogenous retinal detachment (&lt; 4 weeks) in study eye

          2. Scheduled for pars plana vitrectomy for retinal detachment repair without combined
             cataract surgery in study eye

          3. Elevated protein levels in anterior chamber fluid (laser-flare value ≥ 15.0 pc/ms) in
             study eye

          4. Female or male patient ≥ 18 years of age

          5. Written informed consent

        Exclusion Criteria:

          1. Retinal detachment lasting &gt; 4 weeks in study eye

          2. Traumatic retinal detachment in study eye

          3. Giant retinal tears in study eye (size &gt; 3 clock hours)

          4. Visual pre-existing PVR grade C in study eye

          5. Retinal dystrophies in study eye

          6. Scheduled for combined pars plana vitrectomy and cataract surgery for retinal
             detachment repair in study eye

          7. Chronic inflammatory conditions in study eye

          8. Active retinal vascular disease in study eye

          9. Proliferative diabetic retinopathy in study eye

         10. Manifest uveitis in study eye

         11. Endophthalmitis in study eye

         12. Perforating and non-perforating trauma in study eye

         13. Malignant intraocular tumor in study eye

         14. Aphakia in study eye

         15. Uncontrolled glaucoma or ocular hypertension in study eye (intraocular pressure ≥ 30
             mmHg despite IOP lowering therapy)

         16. Previous intraocular surgery except uncomplicated cataract surgery with posterior
             chamber lens implantation in study eye

         17. Cataract surgery in study eye ≤ 3 months ago

         18. Previous retinal procedures (laserpexy, cryopexy, intravitreal gas-injection,
             anti-VEGF or corticosteroid-injection) in study eye ≤ 6 months

         19. Other uncontrolled ophthalmologic disorders

         20. Single eyed patients (BCVA of fellow eye &gt; 1.0 log MAR, &lt; 0.1 decimal, &lt; 1/10 tenth,
             or &lt; 6/60 Snellen fraction [m])

         21. Evidence or history of alcohol, medication or drug dependency within the last 12
             months.

         22. Evidence or history (within the last 12 months) of neurotic personality, psychiatric
             illness that requires or required treatment, epilepsy or suicide risk.

         23. Systemic disorders not compatible with adjuvant application of 5-FU and LMWH via
             intraocular infusion, or not compatible with the local or general anesthesia

         24. Any therapy with immunosuppressant or chemotherapy ≤ 3 months and during the trial
             period

         25. Participation in another trial of IMPs or devices parallel to, or less than 3 months
             before screening, or previous participation in this trial.

         26. Known to or suspected of not being able to comply with the protocol.

         27. Inability to understand the rationale of this trial or the study aim

         28. Any dependency of the patient to the Investigator or the trial site, e.g. employees
             with direct involvement in the proposed trial or in other trials under the direction
             of this Investigator or trial site, as well as family members of the employees or the
             Investigator.

         29. Positive urine pregnancy test, pregnancy or breastfeeding mother.

         30. Women of child bearing potential without satisfactory contraception, i.e. hormonal
             contraceptives for at least 14 days before trial enrolment, IUD, double barrier (women
             of child bearing age must be counselled about the use of adequate contraception).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernd Kirchhof, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Friederike Schaub, Dr.</last_name>
    <phone>004922147886041</phone>
    <email>friederike.schaub@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Augenklinik Uniklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>BW</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Hansjürgen Agostini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanni Molnár, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>STZ eyetrial am Department für Augenheilkunde</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Karl Ulrich Bartz-Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Partsch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Augenheilkunde Uniklinik Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <state>HH</state>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augenklinik Uniklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <state>NRW</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Frank Holz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Fleckenstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Augenklinik Düsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <state>NRW</state>
        <zip>40255</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Rainer Guthoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Schrader, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenklinik der Universität zu Köln</name>
      <address>
        <city>Koln</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049 221 478 86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <contact_backup>
      <last_name>Bernd Kirchhof, MD</last_name>
      <phone>0049 221 478 4105</phone>
      <email>bernd.kirchhof@uk-koeln.de</email>
    </contact_backup>
    <investigator>
      <last_name>Bernd Kirchhof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Hermann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Dahlke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Müther, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Lappas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augenärzte am St. Franziskushospital Münster Augenklinik</name>
      <address>
        <city>Munster</city>
        <state>NRW</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Albrecht Lommatzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Gutfleisch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Sulzbach Augenklinik Sulzbach</name>
      <address>
        <city>Sulzbach</city>
        <state>Saarbrücken</state>
        <zip>66280</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Karl Boden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Januschowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Leipzig Klinik und Poliklinik für Augenheilkunde</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schaub, MD</last_name>
      <phone>0049-221-478-86041</phone>
      <email>friederike.schaub@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Peter Wiedemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Jochmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2016</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

